Tandem Diabetes Profile

USD 2.47  6.4%

Conversion by Dp Vii Associates Lp of 6071 shares of Tandem Diabetes

Tandem Diabetes Care insider trading alert for conversion of series b preferred stock by Dp Vii Associates Lp, the corporate stakeholder, on October 17, 2018. This event was filed by Tandem Diabetes Care Inc with SEC on 2013-11-19. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Tandem Diabetes Summary

Tandem Diabetes Care (TNDM) is traded on NASDAQ General Markets in USA. It is located in 11045 Roselle Street and employs 574 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.22 B. Tandem Diabetes Care conducts business under Healthcare sector and is part of Medical Devices industry. This company has 57.23 M outstanding shares of which 5.47 M shares are at this time shorted by private and institutional investors with about 1.22 trading days to cover. NEUTRAL TANDEM currently holds about 86.5 M in cash with (49.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63.
Check Tandem Diabetes Probability Of Bankruptcy

Ownership Allocation (%)

Tandem Diabetes Target Price Odds Analysis

Odds Below 36.12HorizonTargetOdds Above 36.12
25.83%30 days 36.12 74.06%
Based on normal probability distribution, the odds of Tandem Diabetes to move above current price in 30 days from now is about 74.06% (This Tandem Diabetes Care probability density function shows the probability of Tandem Diabetes Stock to fall within a particular range of prices over 30 days) .

Tandem Diabetes Care Top Holders

Tandem Diabetes Care Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Tandem Diabetes Key Fundamentals

Tandem Diabetes Against Markets

Tandem Diabetes Current Ratings

Tandem Diabetes Care 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Tandem Diabetes Care are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in USA and is traded on NASDAQ General Markets. It employs 574 people. more
NameTandem Diabetes Care
CEO and President and DirectorKim BlickenstaffView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address11045 Roselle Street
ExchangeNASDAQ General Markets
CIK Number0001438133
IndustryMedical Devices
Phone858 366 6900
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestSeptember 28, 2018

Current Sentiment - TNDM

Tandem Diabetes Care Investor Sentiment

Most of Macroaxis users are at this time bullish on Tandem Diabetes Care. What is your outlook on investing in Tandem Diabetes Care? Are you bullish or bearish?
98% Bullish
2% Bearish

Tandem Diabetes Directors

Tandem Diabetes Corporate Directors

Fred Cohen Independent Director
Howard Greene Independent Director
Christopher Twomey Independent Director
Also please take a look at World Market Map. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Search macroaxis.com